European Equities Traded in the US as American Depositary Receipts Climb Higher in Thursday Trading
Novo Nordisk Drops on Q2 Earnings and Sales Miss Despite Raised Outlook
Express News | Novo Nordisk Shares Are Trading Higher. The Stock May Be up After Eli Lily Raised Its Guidance, Primarily Driven by the Performance of Mounjaro and Zepbound
Breaking doubts! The 'weight loss miracle drug' continues to be hot, and Eli Lilly and Co's Q2 performance exceeds expectations and guidance is raised again.
$Eli Lilly and Co (LLY.US)$ Eli Lilly announced its Q2 results on Thursday. According to the data, the company's Q2 revenue was $11.3 billion, a year-on-year increase of 36.0%, better than market expectations; EPS was $3.92, also better than market expectations. thanks to the popularity of the popular weight loss drug Zepbound, the company raised its 2024 revenue guidance for the second time this year. Data showed that Zepbound sales in the second quarter were $1.2 billion, exceeding market expectations of $0.819 billion. Eli Lilly currently expects full-year revenue to be between $45.4 billion and $46.6 billion, higher than previous expectations.
Company News for Aug 8, 2024
Trending Stocks Today | Conduit Pharmaceuticals Shoots up 95.45% Pre-Market